Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Donepezil Hydrochloride NDC 68071-1523 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Structural Formula - 41d7651e b91a 4118 8719 bf2f663d82a2 01
Figure 1 - 41d7651e b91a 4118 8719 bf2f663d82a2 02
This appears to be a table or graph of data related to ADAS-cog change from baseline and clinical improvement for three different treatments. The treatments are Donepezil hydrochloride at 10mg/day, Donepezil hydrochloride at 5mg/day, and placebo. The data is presented as mean values (likely for ADAS-cog change) over a period of weeks of drug treatment. However, without more clear formatting, it is difficult to provide a more detailed description of the data.*
Figure 2 - 41d7651e b91a 4118 8719 bf2f663d82a2 03
The text describes a graph showing the cumulative percentage of patents with respect to the change in the ADAS-cog index for the drug Donepezil hydrochloride. The graph displays two groups, a treatment group, and placebo group. The change in ADAS-cog for the treatment group is between 3 and 7 points, while for the placebo group, it's between 2-5%. The graph indicates the improvement of cognitive functioning as a result of taking Donepezil hydrochloride at a dosage of either 10 or 5 mg/day.*
Figure 3 - 41d7651e b91a 4118 8719 bf2f663d82a2 04
This appears to be a table showing the percentage of patients who were given Donepezil Hydrochloride (either 10 mg/day or 5 mg/day) and a placebo. The table measures the patients' improvement based on the CIBIC-plus Rating scale, marking the degree of improvement from "markedly improved" to "markedly worse."*
Figure 4 - 41d7651e b91a 4118 8719 bf2f663d82a2 05
This is a table showing the ADAS-cog change from baseline in three treatment groups: Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and placebo. The table indicates the mean (+5E) change in scores over weeks of drug treatment and suggests that clinical improvement may have occurred in the treatment groups.*
Figure 5 - 41d7651e b91a 4118 8719 bf2f663d82a2 06
The text appears to be a table showing the percentage change in ADAS-cog test scores for patients being administered 10mg/day and 5mg/day doses of Donepezil hydrochloride compared to a placebo group. The table also mentions a medication called Chsnne foms Buselin but does not provide any further information about it.*
Figure 6 - 41d7651e b91a 4118 8719 bf2f663d82a2 07
This is a table showing the percentage of patients whose condition improved, worsened or stayed the same after taking either 10mg/day or 5mg/day of Aricept or a placebo based on the CIBIC-plus rating. The table has categories for patients who improved markedly, moderately, minimally, had no change, or worsened minimally, moderately, or markedly.*
Figure 7 - 41d7651e b91a 4118 8719 bf2f663d82a2 08
Figure 8 - 41d7651e b91a 4118 8719 bf2f663d82a2 09
Donepezil Hydrochloride 10 mg/day was compared to placebo in a study. No further information is available.*
Figure 9 - 41d7651e b91a 4118 8719 bf2f663d82a2 10
Figure 10 - 41d7651e b91a 4118 8719 bf2f663d82a2 11
pdp - 68071 1523 03 Z15
This text seems to be a mix of a warning label and product information for a medication called Donepezil HCI 10mg in the form of tablets, with a specific expiration date and lot number. It also provides NDC numbers and manufacturing details. The text includes a warning to keep the medication out of reach of children and instructions to store it at a controlled temperature of 59-86 °F.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.